Advertisement
Advertisement
GMAB
Genmab A/S ADS
26.87
USDSponsored
-0.18
-0.67%
May 22, 16:00 UTC -4
Closed
Pre-Market
26.81
-0.06
-0.22%
GMAB Earnings Reports
Positive Surprise Ratio
GMAB beat 26 of 41 last estimates.
63%
Next Report
Date of Next Report
Aug 06, 2026
Estimate for Q2 26 (Revenue/ EPS)
$1.11B
/$2.97
Implied change from Q1 26 (Revenue/ EPS)
+24.29%
/+257.83%
Implied change from Q2 25 (Revenue/ EPS)
+20.39%
/-45.20%
Genmab A/S ADS earnings per share and revenue
On May 07, 2026, GMAB reported earnings of 0.83 USD per share (EPS) for Q1 26, missing the estimate of 1.40 USD, resulting in a -41.03% surprise. Revenue reached 896.00 million, compared to an expected 908.21 million, with a -1.34% difference. The market reacted with a -2.98% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of 2.97 USD, with revenue projected to reach 1.11 billion USD, implying an increase of 257.83% EPS, and increase of 24.29% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Roivant Sciences Ltd. Common Shares
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.35
Actual
-$0.57
Surprise
-64.63%
Belite Bio, Inc - ADR
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.64
Actual
-$0.68
Surprise
-4.87%
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
May 22, 2026 For Q1 26
Estimate
-$1.53
Actual
-$2.35
Surprise
-53.05%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
OS Therapies Incorporated
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.27
Surprise
-49.83%
Annovis Bio, Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.40
Actual
-$0.63
Surprise
-56.37%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
FAQ
What were Genmab A/S ADS's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Genmab A/S ADS reported EPS of $0.83, missing estimates by -41.03%, and revenue of $896.00M, -1.34% below expectations.
How did the market react to Genmab A/S ADS's Q1 2026 earnings?
The stock price moved down -2.98%, changed from $27.89 before the earnings release to $27.06 the day after.
When is Genmab A/S ADS expected to report next?
The next earning report is scheduled for Aug 06, 2026.
What are the forecasts for Genmab A/S ADS's next earnings report?
Based on 6
analysts, Genmab A/S ADS is expected to report EPS of $2.97 and revenue of $1.11B for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement